文章核心观点 - 公司是一家临床阶段的制药公司,专注于开发用于治疗帕金森病及相关疾病的蛋白激酶抑制剂治疗药物 [1][3] - 公司将于2024年8月14日发布2024年第二季度财务业绩,并于次日召开电话会议和网络直播,提供公司更新信息并回顾财务业绩 [1][2] 公司概况 - 公司总部位于佐治亚州亚特兰大,在马萨诸塞州列克星敦也设有办公室 [3] - 公司的多治疗管线主要针对神经退行性疾病,其领先项目risvodetinib是一种Abelson酪氨酸激酶(c-Abl)抑制剂,针对治疗大脑内外的帕金森病及其他由Abelson酪氨酸激酶引起的疾病 [3] - 公司的多治疗管线还在研究与帕金森病相关的大脑和胃肠道疾病、与帕金森病相关的孤儿适应症(如多系统萎缩)以及激酶抑制剂的给药技术,如IkT-001Pro(imatinib间充毒的前药) [3] - 公司的RAMP™化学合成项目已经发现了几个可能应用于大脑认知和运动功能疾病的risvodetinib后续化合物 [3]

CHANDLER, Ariz., Aug. 07, 2024 (GLOBE NEWSWIRE) -- The reliability and performance of Electric Vehicle (EV) chargers are critical to drive global market adoption. EV manufacturers are focused on delivering the most robust, weather-resistant and user-friendly EV chargers. To accelerate the time to market of an EV charger, Microchip Technology (NASDAQ:MCHP) today announces three flexible and scalable EV Charger Reference Designs including a Single-Phase AC Residential, a Three-Phase AC Commercial with Open Ch ...

CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- TransUnion (NYSE:TRU) today announced its partnership with Snowflake, the AI Data Cloud company, to launch TruIQTM Data Enrichment on Snowflake Marketplace. TruIQ Data Enrichment's availability on Snowflake Marketplace will provide joint customers with unlimited, on-demand access to pseudonymized TransUnion credit data in the Snowflake AI Data Cloud. The need for such a solution is clear. According to a recent Forrester Research survey, more than 85% of organizatio ...

SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present at the following investor conferences: Canaccord Genuity 44th Annual Growth Conference Location: InterContinental Boston Hotel, Boston, MA Date: Wednesday, 14 August 2024 Time: 08:30am – 8:55am ET Baird 2024 Global Healthcare Confe ...

THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Posters will be displayed in the poster area of Exhibition Hall B from Friday, August 9 through Sunday, August 12. All three presentations will occur on ...

Unique partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems Abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with Libre technology ABBOTT PARK, Ill., Aug. 7, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global ...

BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinicalstage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. ("Aeries" or "the Company") (NASDAQ:AERT), a global professional services and consulting partner, is confirmed to present at the 2024 Annual Gateway Conference, which is being held September 4-5, at the Four Seasons Hotel in San Francisco, CA. Aeries' management team is scheduled to present on Thursday, September 5 at 8:30 a.m. Pacific Time (PT). In addition to the presentation, Aeries executives will be available for one-on-one meetings th ...

SOMERSET, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the "Company") (NASDAQ:CCLD, CCLDO, CCLDP))), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that Glass Lewis, a leading proxy voting advisory firm, has analyzed CareCloud's Series A Preferred Stock Proposals (the "Preferred Stock Proposals") and recommends a "yes" vote for the proposals at the upcoming special meeting of the holders of CareCloud's 11% Series A Cumulative Rede ...